Your browser doesn't support javascript.
loading
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
Masuda, Jun; Sakai, Hitomi; Tsurutani, Junji; Tanabe, Yuko; Masuda, Norikazu; Iwasa, Tsutomu; Takahashi, Masato; Futamura, Manabu; Matsumoto, Koji; Aogi, Kenjiro; Iwata, Hiroji; Hosonaga, Mari; Mukohara, Toru; Yoshimura, Kiyoshi; Imamura, Chiyo K; Miura, Sakiko; Yamochi, Toshiko; Kawabata, Hidetaka; Yasojima, Hiroyuki; Tomioka, Nobumoto; Yoshimura, Kenichi; Takano, Toshimi.
Afiliação
  • Masuda J; Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
  • Sakai H; Department of Medical Oncology, Toranomon Hospital, Minato-ku, Tokyo, Japan.
  • Tsurutani J; Advanced Cancer Translational Research Institute, Showa University, Shinagawa-ku, Tokyo, Japan sakai-h@med.showa-u.ac.jp.
  • Tanabe Y; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
  • Masuda N; Advanced Cancer Translational Research Institute, Showa University, Shinagawa-ku, Tokyo, Japan.
  • Iwasa T; Department of Medical Oncology, Toranomon Hospital, Minato-ku, Tokyo, Japan.
  • Takahashi M; Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
  • Futamura M; Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
  • Matsumoto K; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
  • Aogi K; Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan.
  • Iwata H; Department of Breast Surgery, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
  • Hosonaga M; Department of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Japan.
  • Mukohara T; Department of Medical Oncology, Hyogo Cancer Center, Akashi, Hyogo, Japan.
  • Yoshimura K; Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan.
  • Imamura CK; Department of Breast Oncology, Aichi Cancer Center, Nagoya, Aichi, Japan.
  • Miura S; Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
  • Yamochi T; Department of Medical Oncology, National Cancer Center-Hospital East, Kashiwa, Chiba, Japan.
  • Kawabata H; Department of Clinical Immuno-oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Shinagawa-ku, Tokyo, Japan.
  • Yasojima H; Advanced Cancer Translational Research Institute, Showa University, Shinagawa-ku, Tokyo, Japan.
  • Tomioka N; Department of Pathology, Showa University, Shinagawa-ku, Tokyo, Japan.
  • Yoshimura K; Department of Pathology, Showa University, Shinagawa-ku, Tokyo, Japan.
  • Takano T; Department of Breast and Endocrine Surgery, Toranomon Hospital, Minato-ku, Tokyo, Japan.
J Immunother Cancer ; 11(9)2023 09.
Article em En | MEDLINE | ID: mdl-37709297
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_breast_cancer / 6_other_malignant_neoplasms Assunto principal: Neoplasias da Mama Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_breast_cancer / 6_other_malignant_neoplasms Assunto principal: Neoplasias da Mama Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão